Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients

Abstract Background Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as...

Full description

Bibliographic Details
Main Authors: Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Rudolf Oehler, Florian Fitzal
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Neoadjuvant chemotherapy
Breast cancer
Immune cells
Epirubicin
Docetaxel
Immunomodulatory markers
Online Access:https://doi.org/10.1186/s13046-023-02876-x

Internet

https://doi.org/10.1186/s13046-023-02876-x

Similar Items